|
|
供應(yīng) Afatinib /439081-18-2 |
規(guī) 格: |
純度:99% |
價(jià) 格: |
550元/10mg/ |
數(shù) 量: |
10mg |
交貨地: |
|
發(fā)布時(shí)間: |
2016-12-02 |
有效期: |
3天 |
備 注: |
Introduction: Afatinib is a candidate drug against non-small cell lung carcinoma, developed by Boehringer Ingelheim. As of December 2008, it is undergoing a Phase III clinical trial for this indication, and Phase II trials for breast, prostate, and head and neck cancers, as well as glioma. In October 2010 a new Boehringer Ingelheim Phase III trial called "Lux-Lung 5" began with this drug.Fall 2010 interim results suggest the drug extended progression-free survival threefold compared to placebo, but did not extend overall survival.
CAS Number: 439081-18-2
Name: N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
Formula: C24H25ClFN5O3
Molecular Weight: 485.94
Deleted CAS: 915958-11-1
Synonyms: Tovok;BIBW 2992;
Density: 1.380 g/cm3
Boiling Point: 676.917 °C at 760 mmHg
Flash Point: 363.186 °C
|
結(jié)構(gòu)式: |
|
|
|